Primary Central Nervous System Lymphoma

被引:13
|
作者
Gerstner, Elizabeth R. [1 ,2 ]
Batchelor, Tracy T. [1 ,2 ,3 ]
机构
[1] Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Canc, Dept Neurol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Boston, MA 02114 USA
关键词
PRIMARY CNS LYMPHOMA; HIGH-DOSE METHOTREXATE; NON-HODGKINS-LYMPHOMA; PHASE-II; DEFERRED RADIOTHERAPY; EUROPEAN ORGANIZATION; MALIGNANT-LYMPHOMA; FOLLOW-UP; CHEMOTHERAPY; BRAIN;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Primary central nervous system (CNS) lymphoma (PCNSL), an uncommon variant of extranodal non-Hodgkin lymphoma (NHL), can affect any part of the neuraxis including the eyes, brain, leptomeninges, or spinal cord. It accounts for approximately 3% of all the primary CNS tumors diagnosed each year in the United States. Congenital or acquired immunodeficiency is the only established risk factor for PCNSL, and individuals with human immunodeficiency virus (HIV) infection are at greater risk for developing this tumor. Infection with HIV likely accounted for the increased incidence in PCNSL observed from 1970 to 2000, but over the last decade the number of cases of PCNSL has stabilized or decreased to about 0.47 cases per 100 000 persons. Owing to the rarity of PCNSL, the disease has been challenging to study and an effective standard of care has been difficult to establish. Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host.
引用
收藏
页码:291 / 297
页数:7
相关论文
共 50 条
  • [21] Rituximab with high-dose methotrexate in primary central nervous system lymphoma
    Kansara, Roopesh
    Shenkier, Tamara N.
    Connors, Joseph M.
    Sehn, Laurie H.
    Savage, Kerry J.
    Gerrie, Alina S.
    Villa, Diego
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (12) : 1149 - 1154
  • [22] Primary central nervous system lymphoma: what a neurologist/neurosurgeon should know?
    Perini, Guilherme Fleury
    Campregher, Paulo Vidal
    de Souza Santos, Fabio Pires
    Hamerschlak, Nelson
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2013, 71 (04) : 254 - 257
  • [23] The Challenge of Primary Central Nervous System Lymphoma
    Carnevale, Julia
    Rubenstein, James L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) : 1293 - +
  • [24] Updates on Primary Central Nervous System Lymphoma
    Schaff, Lauren R.
    Grommes, Christian
    CURRENT ONCOLOGY REPORTS, 2018, 20 (02)
  • [25] Management of primary central nervous system lymphoma
    Royer-Perron, Louis
    Hoang-Xuan, Khe
    PRESSE MEDICALE, 2018, 47 (11-12): : E215 - E246
  • [26] Advances in Primary Central Nervous System Lymphoma
    Therkelsen, Kate E.
    Omuro, Antonio
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2025, 25 (01)
  • [27] Surgery for Primary Central Nervous System Lymphoma: Is It Time for Reevaluation?
    Bierman, Philip J.
    ONCOLOGY-NEW YORK, 2014, 28 (07): : 632 - 637
  • [28] Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry
    Mocikova, Heidi
    Pytlik, Robert
    Sykorova, Alice
    Janikova, Andrea
    Prochazka, Vit
    Vokurka, Samuel
    Berkova, Adela
    Belada, David
    Campr, Vit
    Buresova, Lucie
    Trneny, Marek
    LEUKEMIA & LYMPHOMA, 2016, 57 (12) : 2777 - 2783
  • [29] Radiosurgery as Salvage Therapy for Primary Central Nervous System Lymphoma
    Chen, Clark C.
    Hochberg, Fred
    Batchelor, Tracy
    Shih, Helen A.
    Chakravarti, Arnab
    Chapman, Paul
    Loeffler, Jay
    RADIOSURGERY, VOL 7, 2010, 7 : 276 - 287
  • [30] The role of additional radiotherapy for primary central nervous system lymphoma
    Zacher, Jonas
    Kasenda, Benjamin
    Engert, Andreas
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (06):